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Abstract
Background: Main risk factor for the development of chronic obstructive pulmonary disease (COPD) is smoking,
although only less than 1/3 of smokers develop clinically manifest COPD. COPD’s progressive nature with high
disability and mortality makes it plausible to detect it as early as possible thus allowing for an early intervention.
The only tool for an early diagnosis that could be used on the global scale is spirometry, even though symptoms
and deprivation of health related quality of life (HRQoL) precede relevant spirometric changes. Existing HRQoL
questionnaires are too complicated or not developed for an early detection of COPD. The aim of our study was
to develop a new simple HRQoL tool that will allow (alone or in combination with other markers) early detection
of patients with COPD.
Methods: A multicenter prospective cohort study recruiting 500 subjects at risk for COPD (smokers/ex-smokers ≥20
pack-years, 40–65 years, both sexes, with no prior diagnosis of COPD) will be carried out in two phases: (1) cross-
sectional - development and validation of a new questionnaire; and (2) prospective - follow-up of a cohort of
patients at risk for COPD. Subjects were recruited by 25 GPs and assessed for COPD by dedicated pulmonologists
in 7 hospital centers using a predefined protocol: HRQoL, history, physical, blood sampling, exhaled breath
temperature (EBT), lung function, 6-min walk test (6MWT). Patients without COPD and those in GOLD stage 1
at initial assessment will be reassessed for disease progression by the same pulmonologist after 2 and 5 years.
Discussion: This is one of the first cohort studies attempting to establish the incidence of COPD in the pre-
symptomatic stage before significant end organ damage. We intend to assess the validity, predictability and
discriminative power (‘healthy’ smokers vs. pre-symptomatic phase in newly developed COPD) of newly developed
HRQoL tool alone or in combination with other markers; EBT, lung function, 6MWT, genomics, transcriptomics,
proteomics). We expect that the results of this study can improve our understanding of the development of COPD,
identify some new underlying pathophysiological pathways, and offer to sensitive smokers/ex-smokers new
preventive and early intervention measures thus improving the management of COPD.
Trial registration: Clinicaltrial.gov NCT01550679 retrospectively registered February 28, 2012.
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Background
Chronic obstructive pulmonary disease (COPD) is a
major cause of morbidity and mortality globally, respon-
sible for approximately 5 million deaths every year, with
expected significant rise in mortality untill the year
2020. COPD mortality is low at age 45, but significantly
rises after the age of 65 with significant comorbidity
already present. COPD has a major economical and pub-
lic health impact especially with regard to severe disease
and exacerbations. Major risk factor for COPD develop-
ment is tobacco smoke, although only less than 1/3 of
smokers develop COPD during their lifetime. Because of
its progressive nature COPD ends with early disability
and mortality. Stopping or slowing down the progression
of the disease is still an unmet need, although thera-
peutic interventions in COPD patients have shown to
have significantly larger impact if they were started earl-
ier in the course of the disease [1–4]. An early diagnosis
should allow for an early intervention, thus possibly pre-
venting the progression of COPD, alleviating symptoms
and improving general wellbeing, preventing complica-
tions and comorbidities and early mortality [5]. The only
available method for an early diagnosis that is suitable
for screening purposes is spirometry (also used as the
‘gold standard’ for COPD diagnosis). Although screening
on a global scale is not recommended by COPD guide-
lines, recommendations for early diagnosis (case finding)
have been heavily advocated [6, 7]. New insights of the
genetic background of COPD development have been
revealed from cross-sectional large scale genetic studies
but these data still need confirmation on a global scale
using prospective data [8]. On the other hand, symptoms
and loss in health related quality of life (HRQoL) often
precede diagnostically relevant loss of lung function
(FEV1/FVC <0.7 or < lower limit of normal [LLN]) [6].
Consequently we need new simple tools to detect
patients in an early (pre)symptomatic stage of COPD
before significant end organ damage. Based on these as-
sumptions; the possibility of identifying the population
at risk and the possibility of producing significant benefit
for the patient if COPD is identified early, we decided to
develop and test a new tool (to be used alone and in
combination with other markers) in a prospective cohort
study in a population at risk (smokers/ex-smokers with
significant cumulative exposure to tobacco smoke, with
no prior diagnosis of COPD). This new tool should be
based on a prerequisite for a screening tool; usable on a
global level, cheap, self-applicable, moderate to high sen-
sitivity and high specificity (no false positives) for COPD.
As existing HRQoL questionnaires are too complicated
(Chronic Respiratory Questionnaire - CRQ, St. George
Respiratory Questionnaire - SGRQ), and/or not devel-
oped for the purpose of early detection of COPD (Clin-
ical COPD Questionnaire - CCQ, COPD Assessment
Test - CAT), we have constructed, developed, and intend
to validate a simple self-applicable questionnaire to
detect early changes in HRQoL related to future COPD
development [9–13].
Methods
The aim, design and setting of the study
The aim of this two phase prospective observational co-
hort study in subjects at risk for COPD was to construct,
develop and validate a new tool (newly constructed self-
applicable HRQoL questionnaire – MARKO question-
naire) to be used alone or in combination with other
markers (exhaled breath temperature [EBT], lung func-
tion, inflammatory markers, and omics) in order to iden-
tify subjects who will develop COPD, even before
significant end organ damage that can be identified
using spirometry.
The MARKO study is a prospective, observational,
non-interventional cohort study of subjects (both sexes)
at risk for the development of COPD (smokers/ex-
smokers with a smoking history of ≥20 pack-years),
without a previous diagnosis of COPD. The study for all
investigational sites was approved by the Children’s
Hospital Srebrnjak Ethics Committee and performed in
accordance with the Declaration of Helsinki, good clin-
ical practice, and all relevant international and national
legislations. According to a national legislation regarding
non-interventional studies an approval from a single
local ethics committee meets the ethical requirements
for such a study. The MARKO study has been carried
out with the cooperation of 25 general practitioners
(GPs) and 7 tertiary hospital research centers (within
Departments of Pulmonology) since 2010 (Table 1).
Primary endpoint: to develop and validate the MARKO
questionnaire to be used alone or together with other
markers to identify subjects that will develop COPD.
Secondary endpoints: (a) to evaluate psychometric char-
acteristics of the MARKO questionnaire; (b) to evaluate if
the developed screening questionnaire together with the
COPD-6TM measurement discriminates COPD patients
with GOLD stage 0 (symptomatic smokers) and GOLD 1
from ‘healthy’ smokers and patients with COPD GOLD 2
or higher based on the evaluation made by the pulmonol-
ogist; (c) to determine the rate of progression of COPD in
patients with GOLD 0 during the follow-up; (d) to deter-
mine the prevalence of concomitant disorders in this
population; (e) to identify diagnostic parameters that
are most sensitive for early impairment in COPD (best
discriminate between COPD GOLD 0 and GOLD 1); (f )
to compare the MARKO questionnaire with diagnostic
tools used for evaluation of patients (SGRQ, CAT,
history, physical, lung function, 6MWT); (g) to assess
the prevalence of different stages of COPD (specifically
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GOLD 0 and GOLD 1) in the population at risk for
COPD and in the general population.
MARKO is a two phase study: Phase I - a cross-
sectional; Phase II - prospective, observational, non-
interventional cohort study. Flow diagram of subjects
through the MARKO study is presented in Fig. 1 and
all the assessments during the study are summarized
in Table 2.
Table 1 The list of study sites and researchers involved in MARKO study (MARKO study group)
Study sites Contact person/researcher Role
Children’s Hospital Srebrnjak, Zagreb, Croatia Assoc.Prof. Davor Plavec, MD, MSc, PhD Principal Investigator
General Hospital Dubrovnik, Dubrovnik, Croatia Žarko Vrbica, MD, MSc Principal Investigator
University of Liverpool, Liverpool, UK Prof. Peter MA Calverley, MD, PhD Study consultant
University of Zagreb Centre for Croatian Studies, Zagreb, Croatia Assist.Prof. Adrijana Košćec Đuknić, PhD Psychologist
Institute for Medical Research and Occupational Health, Zagreb, Croatia Assist.Prof. Biserka Radošević-Vidaček, BA, MA, PhD Psychologist
University Hospital Center Osijek, Osijek, Croatia Marina Labor, MD, PhD Co-Investigator
Slavica Labor, MD, PhD Subinvestigator
Iva Jurić, MD Subinvestigator
University Hospital Center Split, Split, Croatia Assist.Prof. Ivan Gudelj, MD, PhD Co-Investigator
Univerity Hospital Center Rijeka, Rijeka, Croatia Assist.Prof. Ljiljana Bulat Kardum, MD, PhD Co-Investigator
University Hospital Dubrava, Zagreb, Croatia Assoc.Prof. Neven Tudorić, MD, PhD Co-Investigator
Đivo Ljubičić, MD Subinvestigator
University Hospital Center Zagreb, Zagreb, Croatia Assoc.Prof. Sanja Popović Grle, MD, PhD Subinvestigator
Special Hospital for Lung Diseases, Zagreb, Croatia Tajana Jalušić Glunčić, MD Subinvestigator
Tina Lukić, MD Subinvestigator













Rosanda Rosandić Piasevoli, MD
Vanja Viali, MD






General Practice office, Donji Muć, Croatia Karla Tudja, MD
General Practice office, Postira, Croatia Nataša Mrduljaš-Đuić, MD
General practice office, Rijeka, Croatia Assoc.Prof. Ines Diminić Lisica, MD, PhD
General Practice office, Strmec Samoborski, Croatia Ines Balint, MD
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In Phase I up to 700 subjects will be recruited with the
risk of COPD by 25 GP’s offices (representing 25 GPs)
in and around 4 major cities. Patients were approached
by their GP during any (unrelated to respiratory prob-
lems) visit to the GP’s office if they were smokers or ex-
smokers of the predefined age group for the study and
were prescreened for inclusion/exclusion criteria using a
structured interview. Eligible patients were given the
Informed consent document with enough time to read it
and to discuss any relevant issues regarding the study
before consenting. All participants signed written
consent for the follow-up study, and separately for bio-
banking of blood for omics (DNA, RNA, serum and
plasma) before taking part in the study and before any
procedure was done. Inclusion criteria for the study
were defined as: written consent; smokers/ex-smokers;
both sexes; aged 40–65 years at inclusion; smoking his-
tory of at least 20 pack-years (calculated as a number of
cigarettes smoked per day multiplied by the number of
years of smoking divided by 20); and no previous diag-
nosis of COPD. Exclusion criteria were defined as: any
clinically relevant chronic disease (cardiovascular, cere-
brovascular, diabetes, hepatitis, nephropathy, chronic
dialysis, systemic disorder, cancer) significantly affecting
HRQoL; ongoing immunosuppressive therapy; preceding
acute respiratory disease 4 weeks before inclusion;
hospitalization for any reason during the past 3 months;
myocardial infarction (MI), cerebrovascular infarction
(CVI) or transient ischemic attack (TIA) during the past
6 months; diagnosis of asthma; and an inability to
perform the diagnostic protocol. Exclusion criteria were
introduced in order not to exclude patients with
Fig. 1 Flow chart of subjects through the MARKO study
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comorbidities common in COPD, but to exclude those
that represent acute/subacute clinical states/disorders or
states of recovery from major clinical disorders repre-
senting an absolute or relative contraindication for
spirometry or significantly influencing the diagnostic
process or an already present diagnosis of respiratory
disorder (e.g., asthma). After inclusion patients fill out
the self-applicable MARKO questionnaire in the GP’s
office and measurement of lung function is done using
COPD-6™ (4000 COPD-6™ Respiratory Monitor, Vitalo-
graph Ltd., Buckingham, UK) recording the values of
forced expiratory volume in 1 s (FEV1), forced expiratory
volume in 6 s (FEV6 - as a surrogate marker of forced
vital capacity [FVC]), FEV1/FEV6 (as a surrogate marker
of FEV1/FVC), and lung age. Two to 4 weeks after inclu-
sion eligible patients are referred to one of the 7 tertiary
hospital research centers, to a designated team consisting
of a pulmonologist, research nurse and lung function la-
boratory technician where a structured diagnostic workup
consisting of the MARKO questionnaire, HRQoL ques-
tionnaires (SGRQ and CAT), structured history and phys-
ical, exhaled breath temperature (EBT) before (EBTb) and
after a smoked cigarette (EBTc), lung function testing with
bronchodilator (salbutamol), impulse oscilometry (only
in one center), lung diffusion capacity (DLCO), body
plethysmography (only in one center), blood sampling
(hematology; highly sensitive C-reactive protein [hs-CRP];
blood for DNA, RNA, plasma and serum), functional ex-
ercise capacity using 6-min walk test (6MWT), ending
with the assessment for diagnosis and severity of COPD
according to the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) and according to the American
Thoracic Society/European Respiratory Society (ATS/
ERS) recommendation for airway limitation using lower
level of normal (LLN) [6, 14].
In Phase II up to 500 subjects will be recruited from
Phase I, assessed by designated pulmonologists as
‘healthy’ smokers, symptomatic smokers (GOLD 0) and
as COPD GOLD 1. Selected subjects will be followed for
at least 5 years; first assessment after 2 years (±2 months)
and the second 5 years (±2 months) after the baseline.
During the first 2 years of follow-up all subjects will
have regular lung function measurement using COPD-
6TM at their GP’s office in 6 month intervals. All subjects
Table 2 List of subjects’ assessment through different stages of MARKO study
Assessment Time/place
0 2-4 6 12 18 24 60
w m m m m m




MARKO questionnaire X X X X
CAT X X X
SGRQ X X X
History X X X
Physical X X X
EBT before and after cigarette X
Lung function
COPD-6™ X X X X X
Spirometry with bronchodilator test X X X
Impulse oscilometrya X
Lung diffusion capacity X
Body plethysmographya X
Blood sampling (hematology; highly sensitive C-reactive protein; blood
stored for DNA, RNA, plasma and serum)b X
Functional exercise capacity (6-minute walk test) X
COPD diagnosis X X X
Legend: w - week, m - month, GP - general practitioner’s office, P - pulmonologist at tertiary care hospital, CAT - COPD Assessment Test, SGRQ - St. George
Respiratory Questionnaire, EBT - exhaled breath temperature
aImpulse oscilometry and body plethysmography was done only in one center
bBlood sampling was done only in subjects that signed additional Informed consent
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will be assessed by the same pulmonologist for diagnosis
and severity of COPD according to GOLD and ATS/ERS
after 2 and 5 years for the progression of disease defined
by three outcome measures: (1) newly diagnosed COPD
(ND COPD); (2) disease progression (DP; newly diag-
nosed COPD + progression to higher severity stage); and
(3) high rate of loss of lung function (LoLF; >70 mL/year
for post bronchodilator FEV1). Incidence of newly diag-
nosed COPD after 2- and 5-years of follow up will be
used to identify diagnostic parameters that are most sen-
sitive for early impairment in COPD, to determine the
predictability of developed screening MARKO question-
naire alone or with other markers of early impairment in
COPD. Blood samples from a subsample of patients who
give the consent for omics research will be used to
develop omics markers predictive for the future develop-
ment of COPD and disease progression.
This research will attempt to answer to following
questions: (1) can we identify cheap and simple tools
that will allow a precise and accurate identification of
subjects from a population at risk of developing COPD
in the future; (2) is there a combination (pattern) of
tools, functional parameters, genetic and biochemical
markers that can reliably predict the development of
COPD in a population at risk, thus allowing early
intervention.
Methods
Screening questionnaire (MARKO questionnaire)
The MARKO questionnaire is a newly constructed
HRQoL questionnaire developed by a group of experts;
three experienced pulmonologists (ZV, DP, PMAC) and
two psychologists (BRV and AKD). The questionnaire
comprises 18 questions covering the manifestation and
frequency of the symptoms already present at early
stages of COPD that could impact the HRQoL in pa-
tients. The participants were asked to rate the frequency
of their symptoms over a designated period of time (e.g.,
over the past three months for coughing, shortness of
breath, expectoration, and over the past 12 months for
pulmonary infections). They also rated their breathing
quality and general health status. Furthermore, they re-
ported on shortness of breath during daily life activities
requiring different physical strain, and compared their
physical abilities and fatigue with respect to their ref-
erential age group. The total scores ranged from 0 to
57 points, where the higher scores indicated poorer
HRQoL.
Other HRQoL questionnaires
HRQoL will be additionally assessed using 2 standard
questionnaires; St. George Respiratory Questionnaire
(SGRQ) and COPD Assessment Test (CAT). The SGRQ
is a standardized self-administered airways disease-specific
questionnaire divided into three subscales: symptoms (8
items), activity (16 items), and impacts (26 items). SGRQ
scores were calculated using score calculation algorithms
and missing data imputation (if the total number of miss-
ing items was ≤10) using the Excel® SGRQ calculator. For
each subscale and for the overall questionnaire, scores
range from zero (no impairment) to 100 (maximum im-
pairment) [10, 11]. The CAT is a validated, short (8-item)
and simple patient completed questionnaire, with good
discriminant properties, developed for use in routine
clinical practice to measure the health status of patients
with COPD. Every item has a scale of 0–5 so the
scoring range is from zero (no impairment) to 40 (max-
imum impairment) [13]. Both HRQoL questionnaires
were self-completed by patients before any other pro-
cedure was done and after the MARKO questionnaire.
Lung function
Spirometry was performed using computerized pneumo-
tachographs (Jaeger®, CareFusion, CA, USA) using the
same procedure at all clinical sites (lung function labs at
tertiary hospitals) in agreement with the ATS/ERS
standardization [15]. The best of three technically satis-
factory efforts was recorded. Bronchodilator test was
done with repeated spirometry 20 min after inhalation
of 400 mcg of salbutamol using the inhalation chamber.
Spirometric parameters (FVC, FEV1, FEV1/FVC ratio,
peak expiratory flow [PEF], forced expiratory flow
between 25 and 75% FVC [FEF25–75]) were recorded as
absolute values and as percentage of predicted according
to Quanjer [16].
Impulse oscillometry (IOS) was done using Jaeger
MasterScreen IOS (Viasys Healthcare, Inc., Yorba Linda,
USA) for measurements of respiratory system impedance
according to ATS/ERS recommendations and the follow-
ing IOS data were collected: resistance of the respiratory
system at 5 Hz (R5) and 20 Hz (R20) and reactance at 5 Hz
(X5) [17]. Results were analyzed as absolute values and as
percentages of predicted values (%) according to reference
equations provided by the manufacturer [18].
Lung volume studies were carried out using a body-
plethysmograph (Ganzhorn, Germany) according to ATS/
ERS recommendations [19]. The following parameters
were analyzed: airway resistance (RAW), expiratory airway
resistance (RAWex), total lung capacity (TLC), residual
volume (RV) and the RV/TLC ratio and expressed as
percentages of predicted values according to ATS/ERS
recommendations [19, 20].
Single-breath diffusing capacity of the lung for carbon
monoxide (DLCO) was measured using a rapid carbon
monoxide and helium analyzer (Ganzhorn, Germany),
which was calibrated prior to each measurement. Values
for DLCO and DLCO corrected for alveolar volume (VA)
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[DLCO/VA] were obtained and are reported as percent
predicted values [21].
Exhaled breath temperature
EBT was measured using X-Halo® device (Delmedica
Investments, Singapore) according to previously vali-
dated method [22]. Patients were requested to inhale
freely through the nose and to exhale through the
mouth into the device at a rate and depth typical of their
normal tidal breathing pattern. The maneuver was con-
tinued until the software of the instrument indicated
that the measured value was stable, thus fulfilling the
criteria of a previously described mathematical model.
The tests were carried out at room temperature of 19–
25 °C, and at relative humidity of 30–60% in the lung
function lab where the atmosphere is controlled and
measured. EBT was measured twice on the same occa-
sion (during the initial visit); (1) baseline measurement
before any other procedure (lung function, bronchodila-
tor test, 6MWT) at least 1 h after the last smoked
cigarette (EBTb) and (2) done only in active smokers
15 min after a smoked cigarette (EBTc) and recorded
with precision of 1/100 of a °C. No other procedure
apart from cigarette smoking was carried out between
the two EBT measurements.
Blood sampling and storage
Before initializing the sample collection process, it was
important to ensure the correct order of blood collec-
tion. The PAXgene blood RNA tube had to be the last
tube drawn in the study procedure process. Before sam-
ple collection, all tubes were labeled with patient identi-
fication number. Blood samples for serum were drawn at
minimal volume of 3 ml in serum separation vacuum
tubes (containing Z Serum Clot Activator gel) and sent to
the laboratory. Samples were kept at room temperature
for at least 30 min, but had to be processed within 2 h of
blood collection. Upon centrifugation at 3000 rpm for
10 min, a minimum of 300 μl of serum was separated for
further detection of hs-CRP level. The rest of the serum
sample from every subject was transferred to a cryotube
vial and stored at −20 °C.
Blood samples for plasma were drawn at minimal vol-
ume of 3 ml in K2EDTA vacuum blood collection tubes
and were inverted several times to ensure proper mixing
of additive with blood. Samples were sent to the labora-
tory where 200 μl of blood was separated for the pur-
pose of complete blood cell hematological analysis. The
remaining blood volume was kept at room temperature
for at least 30 min, but had to be processed within
2 h of blood collection. Samples were then centri-
fuged at 3500 rpm for 10 min. The plasma sample
from every subject was transferred to a cryotube vial
and stored at −20 °C.
Blood samples for DNA extraction were drawn at min-
imal volume of 2 ml in K2EDTA vacuum blood collec-
tion tubes and were inverted several times to ensure
proper mixing of the additive with blood. Samples were
sent to the laboratory where they were kept at room
temperature for 30 min, and inverted again before their
transfer to a cryotube vial which was stored at −20 °C.
Blood samples for RNA extraction were drawn at volume
of 2.5 ml in PAXgene blood RNA tubes, which were kept
at room temperature prior to use. After blood collection,
the PAXgene blood RNA tubes were immediately gently
inverted 8–10 times to ensure proper mixing of additive
with blood, after which they were stored at −20 °C.
Laboratory analyses were done in local laboratories
and included complete blood count, white blood cells
differential count, hematocrit, hemoglobin and hs-CRP.
Functional exercise capacity was assessed using 6MWT
according to the ATS guidelines and expressed as walked
distance in meters and as % of predicted according to
Trooster et al. [23, 24].
Data analyses
Data analyses are envisaged using STATISTICA version
12 (StatSoft, Inc., OK, USA), MedCalc Statistical Software
version 16.8.4 (MedCalc Software bvba, Ostend, Belgium;
https://www.medcalc.org; 2015) and RUMM2030 (RUMM
Laboratory, Perth, Australia). Sample size calculation was
done based on the following assumptions: we expected to
find 25% patients in different stages of COPD according
to the airflow limitation. We therefore expected that the
sample would consist of 75% of ‘healthy’ and symptomatic
smokers, 12.5% patients with COPD GOLD 1, 6.25% in
GOLD 2 and 6.25% in GOLD 3 or 4 stages at initial visit
with the expected difference in the MARKO questionnaire
scores of 2 points and SD od 2.5 points between
‘healthy’ smokers vs. symptomatic smokers vs. COPD
GOLD 1/2 having a statistical power of >80% with
alpha = 0.05 for the sample size of at least 500 subjects.
The expected yearly incidence rate for GOLD 1 and
progression from GOLD 1 to GOLD 2 is planned at 10/
per 100 patient-years.
Phase I data analysis will primarily focus on primary val-
idation of the MARKO questionnaire (its psychometric
characteristics), convergent and discriminant validity com-
paring data between different subgroups and with other
HRQoL questionnaires (CATand SGRQ). Categorical data
will be compared between subgroups using chi-square test
or Fisher exact test and continuous variables using Mann-
Whitney U-test and Kruskal-Wallis ANOVA (non-normal
distribution expected). Metric characteristics of the
MARKO questionnaire will also be analyzed using
Cronbach’s alpha, Lin’s concordance and Spearman’s
correlation coefficients, analyzing inner consistency,
Vrbica et al. BMC Pulmonary Medicine  (2017) 17:36 Page 7 of 10
test-retest reliability, and association with other mea-
sures of HRQoL and health status.
Phase II data analysis will focus on secondary valid-
ation of the MARKO questionnaire to determine the
construct validity and predictability (alone or in combin-
ation with other markers) for future development and/or
progression of COPD. Construct validity of the MARKO
questionnaire will be assessed using factorial analysis to
confirm the number of factors the questionnaire is
measuring with calculations of inter- and intracorrela-
tions between the factors and items. Primary objective
will be to create a questionnaire with the smallest num-
ber of items with reliable predictive properties. Identify-
ing items for potential deletion will be based on a
hierarchical process: age and sex bias, floor and ceiling
effects, item to total correlation and tests of redundancy
(inter-item correlation). Rasch analysis will be used to
identify items with the best fit to a predictive model.
Utility of different markers for disease progression will
be assessed using generalized linear/nonlinear regression
models and expressed as odds ratio (OR) with 95% con-
fidence intervals (CIs). Predictive power for the models
will be presented using receiver operator curve (ROC)
analysis with AUC (with 95% CIs) together with associ-
ated criterion, sensitivity, specificity and positive (PPV)
and negative predictive (NPV) values. P < 0.05 will be
used as statistically significant for all analyses with
correction for multiple comparisons.
Discussion
This is one of the first cohort studies attempting to es-
tablish the predictors and incidence of COPD in pre-
symptomatic stage before clinical diagnosis and clinically
documented end organ damage. Having in mind the
progressive nature of COPD with high morbidity and
early mortality, our aim is to try to develop and identify
simple tools and markers or a pattern of the afore men-
tioned in order to allow diagnosis as early as possible,
before a significant fall in lung function. The problem
when using lung function for diagnosing COPD lies in
the significant variability of what represents normal (ref-
erence) values and the need for a significant expertise in
providing technically appropriate measurement, thus
limiting its use for screening purposes or making an
early diagnosis [13, 14, 25]. Numerous studies have been
focused on testing simple screening tools (questionnaires
and/or simplified flow measurement devices) for already
developed COPD, in order to surpass the limitations of
spirometry obtaining a specificity of up to 84.4%, with in-
adequate blinding between an index test and spirometry
being a major source of bias in these studies [26]. We have
managed to surpass this major bias using the subsample
from Phase I of the MARKO study and showing that lung
function testing with COPD-6™ can substitute spirometry
testing in cases where it is not readily available to the pa-
tient/physician, but bearing in mind that the traditional
cutoff value of <0.7 for FEV1/FEV6 ratio, cannot be the
only criterion for COPD diagnosis and/or further referral
[27]. Early diagnosis and early intervention (based on data
from pathophysiological studies) is highly advocated and
studies already starting chronic bronchodilator treatment
in early stages of COPD (in GOLD stages 1 and 2) have
been initiated [7, 28–30]. In order for it to be possible to
intervene even earlier in the course of disease, with inter-
vention being specific (not harmful), it is very important
for method(s) to be developed to be highly specific in
identifying subjects that will develop COPD. Genetic test-
ing in studies like UK BiLEVE, using large population
samples, showed that contrary to previous genetic studies
significant genetic signals predictive for COPD irrespect-
ive of smoking can be picked up, identifying specific
mechanisms underlying airflow limitation [8]. However
these data should be further confirmed using other popu-
lations and follow-up.
Phase I of the MARKO study will be used to test the
psychometric characteristics of the MARKO question-
naire; to evaluate discriminative power of the MARKO
questionnaire together with COPD-6™ measurements be-
tween different developmental stages of COPD; to identify
diagnostic parameters that are most sensitive for early im-
pairment in COPD (discriminate between COPD GOLD 0
and 1); to compare the MARKO questionnaire with other
measures used to evaluate patients (HRQoL, history, phys-
ical, lung function, functional capacity); and to assess the
prevalence of different stages of COPD (specifically GOLD
0 and 1) in the population at risk for COPD. Preliminary
data from Phase I of initial validation of the MARKO
questionnaire showed the potential for the MARKO ques-
tionnaire to assess early health status changes in smokers
at risk for chronic obstructive pulmonary disease [31].
Although exclusion criteria were introduced to exclude
subjects with acute/subacute clinical disorders or states of
recovery from major clinical disorders representing an
absolute or relative contraindication for spirometry or
significantly influencing the diagnostic process, the
data analysis showed that more than half (56.3%) of
the recruited subjects had one or more (up to 3) co-
morbidities (28.6% hypertension, 10% dyslipidemia,
5.2% diabetes and 4.9% peptic syndrome, etc.) [31].
Phase II of the MARKO study will be used to test the
primary endpoint of the study: to validate the MARKO
questionnaire as a tool to be used alone or combined with
other markers in identifying subjects at risk (smokers/ex-
smokers with relevant exposure to tobacco smoke) who will
develop COPD during the follow-up. Based on previously
published data that EBT could be a sensitive marker of
airways inflammation [21] we introduced it as a possible
predictive marker for future COPD. Recently published
Vrbica et al. BMC Pulmonary Medicine  (2017) 17:36 Page 8 of 10
data from Carpagnano GE et al., and from our group (pre-
liminary data from the MARKO study) showed the sensitiv-
ity of EBT to cigarette smoke and the potential to predict
future development of COPD in current smokers [32, 33].
All other parameters were measured/gathered at the
start of the study for a detailed phenotype/endotype of
recruited subjects and as possible predictive markers
for future COPD.
We anticipate that the MARKO study will give us
answers regarding the predictability and discriminative
power of a newly developed HRQoL tool (MARKO ques-
tionnaire) alone; or in combination with other markers,
such as EBT (using new protocol of assessment) [33], lung
function, 6MWT, genomics, transcriptomics, proteomics.
We believe that the results of this study will improve our
understanding of the development of COPD, identify some
underlying pathophysiological pathways, and offer to sen-
sitive smokers/ex-smokers the possibility of an earlier
intervention, thus improving the management of COPD.
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